Report: Steve Kaldor exits Ambrx CEO post

The San Diego-based Ambrx will be forging ahead without a captain at the helm--at least for a short time. A spokesperson for the seven-year-old biotech--a promising 2005 Fierce 15 company--tells Xconomy that CEO Steve Kaldor "is taking some time off as he considers other options." She added that Kaldor and the board had decided it was time to find a new chief executive. As biotech scribe Luke Timmerman notes, Ambrx is one of the richest developers in the San Diego hub. It's raised more than...

Genmab CEO Drakeman bows out of the weakened biotech

A day after Genmab's battered stock spiked following renewed rumors of a GlaxoSmithKline takeover, the American CEO of the Danish biotech stood down from the helm and was replaced by the developer's chief scientific officer. Lisa Drakeman (photo) headed the company through its celebrated $2.1 billion partnership with GSK for the leukemia drug Arzerra. But as Reuters notes, the company has run into some trouble in subsequent clinical trials and has had to cut costs twice. Its stock has...